The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Angina Pectoris Drugs Market Over The 2026–2030 Period?
The angina pectoris drugs market has demonstrated significant expansion in recent years. This market is expected to expand from $12.88 billion in 2025 to $13.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. Historically, this growth can be ascribed to the rising prevalence of coronary heart disease, increased recognition of angina symptoms, the advent of beta-blockers, the development of hospital infrastructure, and the expanding use of calcium channel blockers.
The angina pectoris drugs market size is anticipated to experience robust growth over the next few years. It is forecast to expand to $17.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. This projected growth during the forecast period stems from factors such as advancements in precision medicine, the expansion of wearable cardiac monitoring devices, an escalating demand for combination therapies, increased investment in research and development for anti-ischemic agents, and the integration of telehealth into cardiac care. Key trends for the forecast period comprise personalized angina management, the emergence of minimally invasive drug delivery systems, the use of fixed-dose combination therapies, a steadily growing geriatric patient population, and the widespread adoption of telemedicine and remote cardiac monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp
Which Drivers Are Supporting The Angina Pectoris Drugs Market Growth?
The increasing prevalence of cardiovascular diseases is anticipated to drive the expansion of the angina pectoris drug market moving forward. These diseases encompass a variety of conditions affecting the heart and blood vessels, such as coronary artery disease, high blood pressure, heart failure, and stroke. The growing occurrence of cardiovascular diseases (CVD) can be attributed to factors including an aging population, unhealthy lifestyles, and the widespread obesity epidemic. Medications for angina pectoris, including nitrates, beta-blockers, and calcium channel blockers, are effective in relieving chest pain and discomfort caused by insufficient blood flow to the heart, thus enhancing patients’ overall quality of life. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the escalating prevalence of cardiovascular diseases is a key factor propelling the growth of the angina pectoris drug market.
Which Segments Define The Angina Pectoris Drugs Market Segment Structure?
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
Which Trends Are Influencing Demand In The Angina Pectoris Drugs Market?
Leading companies within the angina pectoris drug market are prioritizing the adoption of new technologies to sustain their market position, as demonstrated by the U.S. Food and Drug Administration’s approval of Labetalol Hydrochloride Injection for treating angina and its role in better serving existing consumers. Additionally, Nitrostat (Nitroglycerin Sublingual Tablets) has been sanctioned by the United States Food and Drug Administration (FDA) for the immediate management or acute prevention of angina pectoris. A concrete illustration of this trend occurred in March 2023, when Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced Labetalol Hydrochloride Injection, USP, in a prefilled syringe. This particular product has also received authorization from the United States Food and Drug Administration. In hospital environments, the 10 mg/2 mL PFS formulation is employed to address severe hypertension and decrease blood pressure.
Who Are The Established Players Within The Angina Pectoris Drugs Market?
Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S
Get The Full Angina Pectoris Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Which Region Is The Leading Market For The Angina Pectoris Drugs Market?
North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Angina Pectoris Drugs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Browse Through More Reports Similar to the Global Angina Pectoris Drugs Market 2026, By The Business Research Company
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Angina Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model